Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tanabe Research Labs Commences Operations At San Diego Facility
TRL started its new operations in May by appointing three new executives, Masaki Yamada as CEO, Toshihiro Hosaka as senior vice president and Roland Newman as VP and
TRL started its new operations in May by appointing three new executives, Masaki Yamada as CEO, Toshihiro Hosaka as senior vice president and Roland Newman as VP and
Axxess Pharma’s facility is about 22,000sqft and manufactures pharmaceuticals, neutroceuticals and dermotologicals. The company is expected to continue the distribution of its own line of pharmaceuticals from its
Abbott said that similar to the FreeStyle Lite blood glucose test strips, the new FreeStyle test strips do not use the GDH-PQQ enzyme, which can be affected by
Sanofi-aventis and Metabolex said that GPR119 receptor agonists (or G-protein coupled receptor 119) are known to exert the effects on glucose metabolism by a dual mode of action
Basilea Pharmaceutica said that the process to re-open Phase III clinical sites for the Isavuconazole trials has started after the completion of the transfer of the investigational new
Chagas disease results from the infection with the protozoan parasite Trypanosoma cruzi that is spread by biting insects. Merck has consulted with international agencies and research organizations to
Tethys said that the patent was issued following an accelerated review procedure which enables innovators to receive a final decision within 12 months of application. PreDx DRS is
Motavizumab is an investigational humanized monoclonal antibody (MAb) being evaluated for its potential to prevent serious lower respiratory tract disease caused by espiratory syncytial virus (RSV) in pediatric
Renhuang said that design patents, that are awarded to recognise shape, pattern, or a combination of the two, in an industrial application, are one of three patent categories
Lapatinib, along with an aromatase inhibitor (AI), is suggested for the treatment of post-menopausal women with hormone receptor (HR)-positive, ErbB2 (HER2) over-expressing metastatic breast cancer and for whom